2021 Annual Meeting - Challenging Cases in Breast Cancer
The session will have two components. First, the moderator will lead a discussion among the panelists of pre-selected difficult cases. These will be chosen to highlight current controversies and uncertainties in the modern management of breast cancer, and also to emphasize recent practice-changing clinical trials. In addition to radiation oncologists, the panel will include a breast medical oncologist and breast surgical oncologist to demonstrate the coordinated multidisciplinary collaboration that is essential in modern breast cancer management. The panel will also be selected to represent a diversity of radiation oncologists and practice patterns. Second, the audience will have an opportunity to both ask questions about the cases previously presented and also to ask the panel questions about challenging cases or situations they have encountered in their own practice. Questions can be asked during the panel, or emailed in advance to the moderator. The amount of time dedicated to each component will depend on the total time for the panel, but it is anticipated that at least 15 minutes will be reserved for audience questions.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, surgeons, nurses and radiation therapists.
Upon completion of this activity, participants should be able to:
- Utilize the most modern literature to make the most up to date treatment recommendations for patients with breast cancer.
- Explain the contribution of a multidisciplinary team to optimize medical decision making in gray-area cases.
- Julia S. Wong, MD, FASTRO, Dana-Farber Cancer Institute and receives compensation from Oncoclinicas.
- Rachel Rabinovitch, University of Colorado has no financial relationships with a commercial interest.
- Julia R. White, MD, FASTRO, The Ohio State University Wexner Medical Center and receives compensation from Exact Science and GHI and Susan G. Komen.
- Mark Basik, McGill University and and receives compensation from Pfizer Canada.
- Antonio Wolff, Johns Hopkins University has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.